Genespire Secures $52 Million in Series B Funding to Advance Gene Therapies for Genetic Diseases

We are excited to announce that GeneSpire, a pioneering biotechnology company based in Milan, Italy, has successfully raised an impressive €52 million in its latest funding round. Established in March 2020 by gene therapy visionary Prof. Luigi Naldini, alongside Dr. Alessio Cantore, Fondazione Telethon, and Ospedale San Raffaele, GeneSpire is dedicated to developing durable and transformative gene therapies aimed at addressing the urgent needs of patients suffering from genetic diseases, particularly primary immunodeficiencies and inherited metabolic disorders. As a spin-off of the renowned SR-Tiget research institute, which is at the forefront of cell and gene therapy innovations, GeneSpire is poised to make significant breakthroughs in the treatment of these challenging conditions. The funding, which comes from esteemed investors including Sofinnova Partners, will be instrumental in advancing GeneSpire’s robust research agenda and accelerating the development of its cutting-edge gene therapy programs. With this financial boost, the company plans to enhance its clinical trial capabilities and expand its pipeline of innovative therapies. GeneSpire's commitment to transforming the landscape of gene therapy not only showcases its potential to change lives but also underscores the growing confidence and investment in the biotechnology sector focused on rare genetic diseases. This funding round is a significant milestone in GeneSpire’s journey and a testament to the strength of its mission to provide hope and solutions for patients and families affected by genetic disorders.